Profound MedicalPROF
About: Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.
Employees: 131
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
22% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 9
0.02% more ownership
Funds ownership: 38.9% [Q1] → 38.92% (+0.02%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]
0% less capital invested
Capital invested by funds: $80.2M [Q1] → $80.1M (-$88.9K) [Q2]
5% less funds holding
Funds holding: 41 [Q1] → 39 (-2) [Q2]
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
Research analyst outlook
We haven’t received any recent analyst ratings for PROF.
Financial journalist opinion
Based on 3 articles about PROF published over the past 30 days
